arrow
P

Paolo Gallipoli

Queen Mary University of London
H指数:27
被引数:3,458

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

WNK1 signalling regulates amino acid transport and mTORC1 activity to sustain acute myeloid leukaemia growth

WNK1信号通路通过调控氨基酸转运和mTORC1活性以维持急性髓系白血病生长

2025-05-270
OAAI
Acute Resistance to BET Inhibitors Remodels Compensatory Transcriptional Programs Via p300 Co-Activation

急性对BET抑制剂的耐药性通过p300协同激活重塑补偿性转录程序

BLOOD
IF23.1
2024-11-050
PRE
Outcomes with single-agent gilteritinib for relapsed or refractory FLT3-mutant AML after contemporary induction therapy
2024-10-250
OAAI
Phosphoproteomics predict response to midostaurin plus chemotherapy in independent cohorts of FLT3-mutated acute myeloid leukaemia
2024-10-010
OAAI
Impact of BCR::ABL1 single nucleotide variants on asciminib efficacy
LEUKEMIA
IF13.4
2024-09-170
OAAI
Stearoyl-CoA desaturase inhibition is toxic to acute myeloid leukemia displaying high levels of the de novo fatty acid biosynthesis and desaturation
LEUKEMIA
IF13.4
2024-08-260
OAAI
The selective prolyl hydroxylase inhibitor IOX5 stabilizes HIF-1α and compromises development and progression of acute myeloid leukemia
2024-04-184
OAAI
Mannose metabolism inhibition sensitizes acute myeloid leukaemia cells to therapy by driving ferroptotic cell death
2023-04-148
OAAI
C/EBPα Confers Dependence to Fatty Acid Anabolic Pathways and Vulnerability to Lipid Oxidative Stress-Induced Ferroptosis in FLT3-Mutant Leukemia

C/ebp α 赋予FLT3-Mutant白血病对脂肪酸合成代谢途径的依赖性和对脂质氧化应激诱导的铁死亡的脆弱性

2023-04-0333
OA
Vitamin B5 and succinyl-CoA improve ineffective erythropoiesis in SF3B1-mutated myelodysplasia
2023-03-0110
OAAI
Mutational synergy during leukemia induction remodels chromatin accessibility, histone modifications and three-dimensional DNA topology to alter gene expression
2021-09-2323
OAAI
Bone Marrow Mesenchymal Stem Cells Support Acute Myeloid Leukemia Bioenergetics and Enhance Antioxidant Defense and Escape from Chemotherapy
2020-11-01135
OAAI
A randomised phase II trial of hydroxychloroquine and imatinib versus imatinib alone for patients with chronic myeloid leukaemia in major cytogenetic response with residual disease
LEUKEMIA
IF13.4
2020-01-1046
OAAI